AAT is an enzyme inhibitor used as an ongoing therapy to help protect lungs of emphysema patients from the damaging effects of inflammation associated with a deficiency in this protein which in normal conditions is produced in adequate quantities. Advocacy groups are working hard to increase identification of alpha-1 antitrypsin deficient patients and physician education on treatment of this disorder for improved healthcare outcomes.